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To date liver transplantation is the only eﬀective treatment for end-stage liver diseases. Considering the potential of pluripotency
and diﬀerentiation into tridermal lineages, induced pluripotent stem cells (iPSCs)may serve as an alternative of cell-based therapy.
Herein, we investigated the eﬀect of iPSC transplantation on thioacetamide- (TAA-) induced acute/fulminant hepatic failure
(AHF) in mice. Firstly, we demonstrated that iPSCs had the capacity to diﬀerentiate into hepatocyte-like cells (iPSC-Heps) that
expressed various hepatic markers, including albumin, α-fetoprotein, and hepatocyte nuclear factor-3β, and exhibited biological
functions. Intravenous transplantation of iPSCs eﬀectively reduced the hepatic necrotic area, improved liver functions and motor
activity, and rescued TAA-treated mice from lethal AHF. 1,1
 -dioctadecyl-3,3,3 ,3
 -tetramethylindocarbocyanine perchlorate
cell labeling revealed that iPSCs potentially mobilized to the damaged liver area. Taken together, iPSCs can eﬀectively rescue
experimental AHF and represent a potentially favorable cell source of cell-based therapy.
1.Introduction
Acute or fulminant hepatic failure (AHF) is a severe liver
injury accompanied by hepatic encephalopathy which causes
multiorgan failure with a high mortality rate. The use
of chemical reagents, such as thioacetamide (TAA) [1–4],
acetaminophen [5], or galactosamine [6, 7], may reproduce
a number of important clinical characteristics of AHF, such
as hypoglycemia, encephalopathy, and increased blood levels
of hepatic enzymes. Consequently, the experimental models
of AHF induced by these chemicals were widely used for
the investigation of the pathophyisology and therapeutic
strategies of AHF.
Liver transplantation has been shown to be an eﬀective
treatment for this liver failure. However, the drawback of the
procedure is the shortage of donor organs combined with
needing the immunosuppressant treatment [8]. Therefore,
transplantation of hepatocytes or hepatocyte-like cells may
provide great promise because cellular therapy is the relative
simple and less invasive procedure. Recently, the use of
embryonic stem cells (ESCs) has attracted attention for
cellular therapy because of their capability to proliferation2 Journal of Biomedicine and Biotechnology
indeﬁnitely and their potential to diﬀerentiate into all types
of cells including hepatocytes [9–12]. Heo et al.’s study
demonstrated that ESCs gave rise to functional hepato-
cytes that eﬀectively integrated into and replaced injured
parenchyma without formation of teratoma in the mouse
model of liver injury [13] .T h e r ei se v i d e n c es u g g e s t e dt h a t
bone marrow (BM) is another source of hepatic progenitors
[14, 15]. However, BM cells also contribute functionally and
signiﬁcantly to liver ﬁbrosis [16]. We should be vigilant for
the possibility of organ ﬁbrosis induced by BM cell-based
therapy.
Induced pluripotent stem cells (iPSCs) are novel stem
cell populations induced from mouse and human adult
somatic cells through reprogramming by transduction of
deﬁned transcription factors [17, 18]. Recent studies further
suggested that iPSCs were indistinguishable from ESCs in
morphology, proliferative abilities, surface antigens, gene
expressions, epigenetic status of pluripotent cell-speciﬁc
genes, and telomerase activity [19]. Previous studies have
shown that both human and mouse iPSCs can eﬃciently
diﬀerentiate into functional hepatocytes in vitro [20, 21],
which may be helpful in studying liver development and
regenerative medicine. In the present study, we ﬁrst diﬀer-
entiated iPSCs into iPSC-hepatocyte-like cells (iPCS-Heps)
using a stepwise protocol and monitored the expression
of hepatic markers on iPCS-Heps. Next, we transplanted
iPSCs into TAA-treated mice and found that iPSCs were
incorporated into livers and signiﬁcantly improved the
hepatic functions, motor activity, and mortality rate of
mice. This cellular therapy opened an era for cell-based
transplantation by overcoming the ethical controversy over
ESCs.
2.MaterialsandMethods
2.1. In Vitro Hepatic Diﬀerentiation. The ﬁrst clone of
murine iPSCs Re7 were generated from mouse embryonic
ﬁbroblasts (MEF) derived from 13.5-day-old embryos of
C57/B6 mice from our lab, and the secondary clone of
murine iPSCs were kindly provided by Dr. Shinya Yamanaka.
The iPSCs were cultured as previously described [17, 18].
iPSCs were seeded at 2 × 104 cells/cm2 maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Invitrogen)
containing10%fetalbovineserum,100U/mLpenicillin,and
100μg/mL streptomycin in gelatin-coated plates, prior to
induction by a 2-step procedure. iPSCs were diﬀerentiated
by using step-1 diﬀerentiating medium, consisting of DMED
supplemented with 20ng/mL HGF (Peprotech), 10ng/mL
bFGF (Peprotech), and 0.61g/L nicotinamide. After 7 days,
step-1 diﬀerentiating medium was changed to step-2 mat-
uration medium containing DMEM supplemented with
0.1μM Nicotinamide, dexamethasone (Dex; Sigma), and 1%
insulin-transferrin-selenium (ITS; Sigma). Medium changes
were performed twice weekly. iPSCs treated with medium
supplemented with no growth factors were used as the
negative control. For embryoid body (EB) formation, iPSCs
were dissociated into a single cell suspension by 0.25%
trypsin-EDTAandplatedontononadherentculturedishesin
DMEM with 15% FBS, 100mM MEM nonessential amino
acids, 0.55mM 2-mercaptoethanol, and antibiotics at a
density of 2 × 106 cells/100mm plate. After 4 days in ﬂoating
culture, EBs were transferred onto gelatin-coated plates and
maintained in the same medium for 24 hours. EBs were
then assigned for in vitro hepatocyte diﬀerentiation by using
a two-step procedure as previously described, with some
modiﬁcations [22].
2.2. RT-PCR. Total RNA was isolated from iPSCs and
diﬀerentiating iPSCs using TRIzol Reagent (Invitrogen).
The messenger RNA of hepatic speciﬁc markers includ-
ing hepatocyte nuclear factor-3β (HNF-3β), α-fetoprotein
(AFP), albumin (ALB), Transthyretin (TTR), α-antitrypsin
(AAT), and tyrosine-aminotransferase (TAT) was reverse
transcribed to complementary DNA (cDNA) using a reverse
transcription system (Promege). cDNA was ampliﬁed using
Taq polymerase (Takara, Japan) at 94◦Cf o r5m i n u t e s ,3 5
cycles of 94◦C for 30 seconds, 55◦C for 30 seconds, 72◦C
for 30 seconds, and extension at 72◦C for 10 minutes. The
primers used are shown in Table 1. The relative expression
of each gene was normalized against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
2.3. Periodic Acid-Schiﬀ (PAS) Stain for Glycogen. Cells were
ﬁxed in 4% paraformaldehyde and then permeabilized with
0.1% Triton X-100 for 10 minutes. Samples were then
oxidized in 1% periodic acid for 5 minutes, rinsed 3 times
in deionized (d)H2O, treated with Schiﬀ’s reagent for 15
minutes, and rinsed in dH2Of o r5t o1 0m i n u t e s .S a m p l e s
were counterstained with Mayer’s hematoxylin for 1 minute
and then rinsed in (d)H2O. With 12 repetitive experiments,
the samples were observed under light microscope.
2.4. Cellular Uptake Assay of Low-Density Lipoprotein
(LDL). The uptake capability of 1,1 -dioctadecyl-3,3,3 ,3 -
tetramethylindocarbocyanine perchlorate conjugated to
acetylated-LDL (DiI-Ac-LDL; AbD Serotec) of iPSCs
and diﬀerentiated cells was determined by ﬂuorescent
microscopy in 12 repetitive experiments. Cells were
incubated with 20μg/mL DiI-AC-LDL at 37◦C for 24 hours.
Incorporation of DiI-Ac-LDL into cells was visualized by
ﬂuorescence microscopy.
2.5. Immunostaining Analysis. C e l l sw e r eﬁ x e di n4 %
paraformaldehydeandthenpermeabilizedinPBScontaining
1% bovine serum albumin and 0.3% Triton X-100 before
incubating with primary antibodies in PBS/BSA at 4◦C
overnight. After washing with PBS, cells were incubated with
rhodamine-conjugated secondary antibodies of anti-HNF-
3β, anti-AFP, and antialbumin at room temperature for 30
minutes. After washing with PBS, the samples were mount-
ing in Prolong Gold with 4,6-diamidino-2-phenylindole
(DAPI; Molecular Probes). Fluorescence-labeled cells were
observed under a ﬂuorescent microscope.
2.6. Cell-Labeling Protocol. In this study, we transplanted
DiI-labeled iPSC to trace the distribution of iPSC. In brief,Journal of Biomedicine and Biotechnology 3
Table 1: The sequences for the primers of RT-PCR.
Gene name Primer sequence Product length
HNF-3β Forward: CAGCTACACACACGCCAAAC 204bp
Backward: GGCACCTTGAGAAAGCAGTC
AFP Forward: TCGTATTCCAACAGGAGG 173bp
Backward: AGGCTTTTGCTTCACCAG
ALB Forward: GCTACGGCACAGTGCTTG 260bp
Backward: CAGGATTGCAGACAGATAGTC
TTR Forward: CTCACCACAGATGAGAAG 225bp
Backward: GGCTGAGTCTCTCAATTC
AAT Forward: AATGGAAGAAGCCATTCGAT 484bp
Backward: AAGACTGTAGCTGCTGCAGC
TAT Forward: ACCTTCAATCCCATCCGA 206bp
Backward: TCCCGACTGGATAGGTAG
GAPDH Forward: CTCATGACCACAGTCCATGC 155bp
Backward: TTCAGCTCTGGGATGACCTT
Abbreviations: hepatocytenuclearfactor-3β:H N F - 3 β; α-fetoprotein:AFP; albumin: ALB; Transthyretin:TTR;α-antitrypsin:AAT;tyrosine-aminotransferase:
TAT; glyceraldehyde-3-phosphate dehydrogenase: GAPDH.
1 × 106 mouse iPSCs were suspended in phosphate-buﬀered
saline in the presence of DiI at a ﬁnal concentration of
1μg/mL and incubated for 10min at 37◦C followed by 5 min
at 4◦C and ﬁnally washed thrice with PBS.
2.7. Animal Model of Liver Injury. Male BALB/c mice, 7-8
weeks old with weighing 25–30g, were used for our exper-
iments. Fulminant hepatic failure was induced by intraperi-
toneal injection of thioacetamide (TAA) (150mg/kg, Sigma)
[23, 24]. Mice were randomly divided into 2 groups: group 1
(phosphatebuﬀersaline(PBS);n = 36)andgroup2(2 ×106
iPSCs; n = 23) via tail vein injection. To avoid hypoglycemia
and electrolyte imbalance [25], subcutaneous injections of
a solution containing 10% glucose water mixed with lactate
ringer (25mL/kg) were performed every 12 hours after the
injection of TAA. Motor activity measurements and blood
sampling were performed 24 hours after the administration
of TAA to observe the immediate hepatic damage. In order
to observe the prolonged hepatic damage, measurement of
motor activity and survival rate and collection of blood
samples were performed 72 hours after the administration of
TAA in iPSCs- and PBS-treated groups. All mice were caged
at24◦Cwitha12-hlight-darkcycleandallowedfreeaccessto
water and food. This study was approved by Taipei Veterans
General Hospital Animal Committee, and the principles of
Laboratory Animal Care were followed.
2.8. Measurement of Motor Activity. Motor activities in an
open ﬁeld were determined by using the Opto-Varimex
animal activity meter (Columbus Instruments Inc.) [26].
The Opto-Varimex activity sensors utilize high-intensity,
modulated infrared light beams to detect animal motion.
Animals were housed in transparent cages (17 inches × 17
inches × 8 inches) through which 30 infrared beams pass in
the horizontal plane, 15 on each axis. This device diﬀerenti-
ates nonambulatory movements (scratching, gnawing) from
ambulation on the basis of consecutive interruption of the
infrared monitoring beams. An additional row of infrared
beams in the horizontal plane (15 on each axis) about 10cm
above the ﬂoor was used to count the vertical movements.
During the activity measurements, animals have no access
to food or chow. All studies were performed under strictly
standardized conditions in the dark room for 30 minutes.
The counting numbers of the total movements, ambula-
tory movements, and vertical movements were separately
recorded to reﬂect the motor activities of rats with fulminant
hepatic failure. The motor activities were deﬁned as zero in
dead mice.
2.9. Liver Functional Tests. Biochemical parameters were
measured using standard clinical methods. After anesthesia
by ketamine (10mg/100g), intracardiac aspiration of blood
was performed. A 0.8-0.9mL of blood sample was collected
from the heart into a pyrogen-free syringe containing ∼75
unitsofheparinsodium,thenplacedinanicebathandtrans-
ported immediately to the laboratory. Serum biochemistry
tests, including alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and total bilirubin, were measured
by Vitro DT chemistry system (Johnson & Johnson).
2.10. Statistical Analysis. Results were expressed as mean ±
S.D. Statistical analyses were performed by using unpaired
Student’st-tests,andthesurvivalrateanalysesusinglog-rank
test. Results were considered statistically signiﬁcant at P<
0.05.
3. Results
3.1. In Vitro Diﬀerentiation of iPSCs into iPSC-Heps. We
introduced retroviruses containing mouse Oct3/4, Sox2,
Klf4, and c-Myc into MEF. These iPS clones were positive for4 Journal of Biomedicine and Biotechnology
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Figure 1: In vitro diﬀerentiation of iPSCs into iPSC-Heps. iPSCs were seeded at 2 × 104 cells/cm2, maintained in Dulbecco’s modiﬁed
Eagle’s medium. (a) Left: Morphology of iPSC colonies. Right: iPSC colonies were positive for alkaline phosphate stain (purple). (b) The
hepatogenic diﬀerentiation was induced by a 2-step procedure as described in Section 2. Morphology of undiﬀerentiated and diﬀerentiated
iPSCs was evaluated at diﬀerent days after hepatogenic diﬀerentiation.
alkaline phosphatase (Figure 1(a)). Under hepatogenic con-
dition, iPSC-derived embryoid bodies (EBs) (Figure 1(b),
upper left) were shifted to hepatic diﬀerentiation media,
and they gradually exhibited broadened and cuboidal mor-
phology with increasing time of induction in vitro and
eventually diﬀerentiated into iPSC-Heps at D7, D14, D21,
and D28 (Figure 1(b)). Immunoﬂuorescence staining with
anti-ALB antibody and anti-AFP antibody was observed
using the confocal microscope in iPSC-Heps, and showed
increased expression of ALB and AFP in iPSC-Heps in
the 28th day diﬀerentiation (Figure 2). In order to conﬁrm
the hepatic characteristics of iPSC-Heps RT-PCR and q-
RT-PCR analyses were performed to examine expression of
hepatic-speciﬁc markers including HNF-3, AFP, ALB, TTR,
AAT, and TAT (mean ± SD, n = 3). Obviously, after
week 2 post diﬀerentiation, the expression of hepatic-speciﬁc
genes was further upregulated in iPSC-Heps compared to
un-diﬀerentiated iPSCs (Figure 3(a)). Besides, expression ofJournal of Biomedicine and Biotechnology 5
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Figure 2: Immunoﬂuorescence staining for several hepatocyte-speciﬁc markers in iPSC-Heps. Immunostaining imaging (800x) results
showed that several hepatocyte-speciﬁc markers detected by using (a) anti-AFP antibody and (b) anti-albumin antibody in iPSC-Heps.
Blue signal indicated DAPI-positive cells.
hepatic speciﬁc genes was signiﬁcantly increased at week 2
after diﬀerentiation in HNF-3β,T T R ,A A T ,a n dT A T ,a n d
at week 3 after diﬀerentiation in AFP and ALB, but not in
undiﬀerentiatediPSCs(Figure 3(b), ∗P< 0.05versusiPSC).
3.2. Functional Characterization of iPSC-Heps. We further
examined whether the iPSC-Heps with high expression of
hepatic-speciﬁc genes also possessed biological hepatic func-
tions. The uptake of LDL was measured by incorporation
rate of DiI-Ac-LDL and the presence of stored glycogen
was determined by PAS staining. Neither cellular uptake
of LDL (mean ± SD, n = 12) (Figure 4(a))n o rg l y c o g e n
synthesis (mean ± SD, n = 12) (Figure 4(b))w a so b s e r v e d
in undiﬀerentiated iPSCs, weeks 1 and 2 after iPSC-Heps
diﬀerentiation. In contrast, iPSC-Heps showed signiﬁcantly
the ability to take up LDL (Figure 4(a)) and store glycogen
(Figure 4(b)) over the three weeks of diﬀerentiation (∗P<
0.05 versus week 0). Thus, the iPSC-Heps resemble hepato-
cytes both morphologically and functionally.
3.3. Intravenous Transplantation of iPSCs Exhibited Beneﬁcial
Eﬀect on Survival Rate, Hepatic Encephalopathy, and Liver
Functions in Mice with AHF. AHF is a severe liver disease
accompanied by high mortality and hepatic encephalopathy
that causes multiorgan failure. We assessed the therapeutic
potential of iPSCs in TAA-induced AHF. We observed that
in iPSCs-treated groups, 7/23 (30.4%) mice were died 72
hours post administration of TAA, whereas 26/36 (72.2%)
mice were died in control groups. These results showed that
the survival rate was signiﬁcantly improved in mice receiving
iPSC transplantation compared to controls (Figure 5(a), P =
0.0018 by log-rank test). Furthermore, we examined whether
iPSC transplantation could improve hepatic encephalopathy
by assessing the motor activity of TAA-treated mice after
iPSCs transplantation. Motor activity assay indicated that 72
hours after TAA administration, the total movements (599 ±
110 versus 246 ± 71, P = 0.006) and ambulatory movements
(364 ± 68 versus 155 ± 45, P = 0.009) were signiﬁcantly
increased in iPSCs-treated groups compared to PBS-treated
groups (Figure 5(b)). These results demonstrated that iPSC
treatment improved TAA-induced hepatic encephalopathy
72 hours after TAA injection.
To evaluate the eﬀects of the 1st clone of iPSC Re7
from our lab on rescuing TAA-induced hepatic failure, we
further evaluated whether this cell therapy also rescued liver
functions in mice with AHF. There were robust increases in
the levels of ALT, AST, and TBIL in PBS recipients 24 hours
after TAA administration. These robust increases in hepatic
biochemical parameters gradually decreased within 72 hours6 Journal of Biomedicine and Biotechnology
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Figure 3: Gene expression of hepatic speciﬁc markers for iPSC-Heps. Expression of hepatic speciﬁc markers including HNF-3β,A F P ,A L B ,
TTR, AAT and TAT was detected by (a) RT-PCR and (b) q-RT-PCR during the hepatogenic diﬀerentiation course of iPSCs. Data shown here
are the mean ± SD. ∗P< 0.05 versus iPSCs.
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Figure 4:FunctionalcharacterizationofiPSC-Heps.TheuptakeofLDLwasmeasuredbyincorporationrateofDiI-Ac-LDLandthepresence
of stored glycogen was determined by PAS staining. Both (a) LDL uptake and (b) glycogen synthesis were evaluated over 4 weeks post-
diﬀerentiation. Data shown here are the mean ± SD. ∗P< 0.05 versus Week 0.
(Table 2). The iPSC transplantation decreased all of these
biochemical parameters at 24 hours and further signiﬁcantly
suppressed them at 72 hours after TAA administration
(Table 2, ∗P<0.05, iPSC versus PBS). Similar results
were identiﬁed in the 2nd clone of iPSC from Dr. Shinya
Yamanaka (Table 3, ∗P<0.05, iPSC versus PBS). These
ﬁndingsdemonstratedthatintravenouslytransplantediPSCs
can eﬀectively rescue TAA-induced hepatic failure, restore
liver functions, and improve survival in mice with AHF.
3.4. iPSC Transplantation Reduced Hepatic Necrotic Area in
MicewithAHF. ToexplorewhethertransplantationofiPSCsJournal of Biomedicine and Biotechnology 7
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Figure 5: iPSCs increase the survival rate and motor activity of recipient mice. Male BALB/c mice were used for evaluation of the
hepatoprotective activity of iPSC in the TAA-treated liver injury model. TAA (150mg/kg) was given via intra-peritoneum injection and
mice were received PBS or iPSCs (2 × 106 cells) via tail vein injection to determinate (a) the survival rate and (b) motor movements. Data
s h o w nh e r ea r et h em e a n± SD. ∗P< 0.05 versus PBS.
Table 2: Eﬀect of intravenous transplantation of PBS or iPSCs clone 1 Re7 from our lab on hepatic biochemical parameters in TAA-treated
recipients.
Alanine aminotransferase (ALT; IU/L) Aspartate aminotransferase (AST; IU/L) Total bilirubin (TBIL; mg/dL)
Recipient after 24 hours
PBS 20702 ± 1631 6956 ± 522 2.0 ± 0.3
iPSCs 5175 ± 509∗ 1932 ± 290∗ 1.3 ± 0.2∗
Recipient after 72 hours
PBS 1721 ± 497 1116 ± 286 1.0 ± 0.2
iPSCs 312 ± 62∗ 248 ± 76∗ 0.5 ± 0.1∗
Results were expressed as mean ± SD. ∗P<0.05 versus PBS.
repairs hepatic necrosis, we compared H&E-stained liver
sections from TAA-treated mice that received infusion of
either iPSCs or PBS via tail vein. After TAA treatment,
AHF happened immediately with obvious hepatic necrosis
area. However, histological examination revealed that the
rescuing eﬀect of transplantation of iPSC clone 1 from
our lab was initially observable in 24 hours than PBS
group, and the numbers of necrotic areas (black arrow) in
iPSC transplantation start to decrease signiﬁcantly (Figures
6(a) and 6(b), ∗P< 0.05 versus PBS). Furthermore,
lymphocyte inﬁltration (hallow arrow) and necrotic areas
(black arrow) were remarkably diminished in 72 hours in
iPSC transplantation (Figures 6(a) and 6(b), ∗P<0.05
versusPBS)iniPSCclone1fromourlab.Similarresultswere
identiﬁed at iPSC clone 2 from Dr. Shinya Yamanaka in 24
and 72 hours (Figure 6(c), ∗P<0.05 versus PBS).
3.5.iPSCsMobilizedtotheDamageAreaofTAA-InjuredLiver.
To further explore the fate of intravenously transplanted
iPSCs from tail vein, we labeled iPSCs with DiI and
explored if the iPSCs could migrate and incorporate into
the damaged liver in TAA-treated mice. As detected by
immunoﬂuorescence staining, we observed that DiI-labeled
iPSCs were found around central veins and were scattered
the damaged liver areas (Figure 7(a) light ﬁeld and 7(b)
dark ﬁeld). This implied that iPSCs can migrate from the
peripheral space into areas of damaged liver in TAA-treated
mice and may have favorable eﬀects on improving liver
functions and motor activity, and rescuing TAA-treated mice
from lethal AHF. These hepatoprotective properties may
subsequently improve hepatic encephalopathy and impaired
motor activity.
4. Discussion
In this present study, we ﬁrst showed that iPSC-Heps can
be generated from iPSCs using the stepwise diﬀerentiation
protocol. We demonstrated that intravenous transplantation
of iPSCs can mobilize to the damaged liver area and
extensively reduced the hepatic necrotic area, improved liver
functions and motor activity, and rescued TAA-treated mice
from lethal in mice with TAA-induced liver failure. Taken8 Journal of Biomedicine and Biotechnology
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Figure 6: Eﬀects of iPS cells on histopathological changes in recipient mice. Results showed the representative H&E stain of TAA-treated
liver tissue receiving iPSCs or PBS treatment after 24 hours or 72 hours in iPSC clone 1 from our lab and clone 2 from Shinya Yamanaka. In
(a) and (b), the necrotic areas in iPSC-treated group were signiﬁcantly reduced than PBS-treated group in 24 hours and 72 hours after TAA
administration in iPSC clone 1. In (c), similar results were identiﬁed in iPSC clone 2. ∗P< 0.05 versus PBS.Journal of Biomedicine and Biotechnology 9
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Figure 7: Mobilization of DiI-labeled iPSCs to the liver of mice with AHF. DiI ﬂuorescent staining was used to trace the migration of the
cells in the body. The transplanted DiI-labeled iPSCs was indicated as red spots under dark ﬁeld microscopy (b) in the damaged liver area in
TAA-treated mice. White arrows indicated the DiI-labeled iPSC and results indicated histological examination under (a) light ﬁeld; (b) dark
ﬁeld.
Table 3: Eﬀect of intravenous transplantation of PBS or iPSCs clone 2 from Dr. Shinya Yamanaka on hepatic biochemical parameters in
TAA-treated recipients.
Alanine aminotransferase (ALT; IU/L) Aspartate aminotransferase (AST; IU/L) Total bilirubin (TBIL; mg/dL)
Recipient after 24 hours
PBS 17768.2 ± 786.9 6875.2 ± 929.1 3.87 ± 0.45
iPSCs 3157.4 ± 336.8∗ 1512.9 ± 257.1∗ 1.53 ± 0.46∗
Recipient after 72 hours
PBS 1553.4 ± 67.1 984.7 ± 26.2 1.53 ± 0.18
iPSCs 217.7 ± 7∗ 175.1 ± 8.4∗ 0.92 ± 0.13∗
Results were expressed as mean ± SD. ∗P<0.05 versus PBS.
together, our data showed that iPSCs can eﬀectively rescue
experimentalAHFandmayprovideanalternativecellsource
to hepatocyte transplantation for acute/fulminant liver dis-
eases. Nevertheless, the underlying mechanisms of iPSC-
mediated therapeutic eﬀect remained largely unknown.
It has been clearly demonstrated that mesenchymal stem
cells (MSCs) have a capacity to mobilize and integrate into
damaged tissues and provide immunomodulatory eﬀects
to undergo tissue repair via paracrine eﬀects [27]. Con-
sequently, MSC transplantation has been regarded as a
new clinical approach for tissue regeneration. Intravenous
transplantation of MSCs has been shown to mobilize to
the damaged liver and improved hepatic functions in mice
with AHF [28]. Interestingly, in the present study, the dis-
tribution of DiI-labeled iPSCs demonstrated that iPSCs
could also mobilize to the damaged area of liver, in a man-
ner similar to that of MSCs. BM-derived MSC is widely
used for MSC-based regeneration study, whereas such cell is
relatively inaccessible [29, 30], and the cell number and the
diﬀerentiatingpotentialofBM-derivedMSCsweredecreased
withage[31]. Given that iPSCs were generated from somatic
cells and exhibited remarkable therapeutic potential on ful-
minanthepaticfailure,iPSCcouldbeanotherchoiceforcell-
based therapy against fulminant hepatic failure.
Cross-gender and whole-liver transplantation studies in
rodents indicate that BM-derived or extrahepatic stem cells
can diﬀerentiate into hepatocytes [32]. Previous studies also
showed that early hepatic precursors can be generated from
ESCs in vitro and these precursors can diﬀerentiate into
functional hepatocytes that rescued and incorporated into
diseased liver parenchyma [13]. Although iPSCs possess
pluripotent properties similar to those of ESCs, whether the
transplanted iPSCs diﬀerentiated into hepatocytes or iPSC-
Heps after incorporation into the liver area was unknown.
We speculated that there were some possible mechanisms for
iPSC-mediatedhepatoprotectiveeﬀect,including(a)restora-
tion of impaired hepatic function by engrafted iPSCs that
may undergo diﬀerentiation and have mature hepatocyte
functions in vivo, (b) stimulating the proliferation of new
functional hepatocytes that may restore hepatic function,
via a paracrine manner, and (c) providing certain imm-
unomodulatory eﬀects similar to those of MSCs and repair
damaged tissue. Nevertheless, further investigations will be
required to clarify these speculations.
Previous studies have demonstrated that iPSCs can dif-
ferentiate into diﬀerent types of cells including cardiomy-
ocytes, endothelial cells, and neural cells in vitro [33–36].10 Journal of Biomedicine and Biotechnology
Given the potential to generate patient-speciﬁc cell popula-
tions without the need for human embryonic cells, iPSC
technology has received great excitement by research and
medical communities. However, many questions regarding
the actual molecular process of induced reprogramming
remain unanswered and need to be addressed. Teratoma for-
mation [37] and genomic instability [38]h a v eb e e nr e p o rt e d
tobethemajorriskinthetransplantationofiPSCsgenerated
by four exogenously introduced genes (Oct4/Sox2/Klf4/c-
Myc). Notably, there are no observable tumor-like structures
in the liver after a follow-up observation for one month
after iPSC transplantation in the present study. To fully
exclude the risk of teratoma formation and nonviral vector
or replaced the pro-oncogens of c-Myc and Klf4 may be a
more safe way and should be developed in the future study.
Comparing with MSCs and ESCs, iPSCs are relatively
accessible and with less ethical issues and immunorejection.
Our results provided evidence that iPSCs can migrate from
systemic circulation to the damaged liver in TAA-treated
mice and immediately improve liver functions and rescue
survival beneﬁt shortly after transplantation. Therefore, this
iPSCtransplantationmayprovideanalternativeoftherapeu-
tic strategy for patients with acute/fulminant hepatic failure.
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